United Therapeutics Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Martine A. Rothblatt
- Full Time Employees
- 1,305
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1040 Spring Street Silver Spring MD United States of America 20910
- IPO Date
- Jun 17, 1999
- CIK
- 0001082554
- Website
- unither.com
- Similar Companies
- Business
- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit biotechnology company founded in 1996 and headquartered in Silver Spring, Maryland, with co-headquarters in Research Triangle Park, North Carolina, develops and commercializes innovative products to address unmet medical needs of patients with chronic and life-threatening diseases, particularly pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), high-risk neuroblastoma, and organ failure; its core commercial portfolio includes Tyvaso DPI and Tyvaso, inhaled formulations of treprostinil via dry powder inhaler and nebulizer for PAH and other lung conditions; Remodulin (treprostinil) injection and Orenitram (treprostinil extended-release tablets) for PAH to improve exercise capacity and delay disease progression; Adcirca (tadalafil), an oral PDE-5 inhibitor for PAH; Unituxin (dinutuximab) injection, a monoclonal antibody for pediatric high-risk neuroblastoma; and Remunity Pump, a subcutaneous delivery system for Remodulin. The company operates in the United States, Canada, Central and South America, Europe, the Middle East, and Asia through distribution partners and maintains manufacturing facilities in locations including Melbourne and Jacksonville, Florida; Blacksburg, Virginia; Manchester, New Hampshire; and Magog and Bromont, Quebec. United Therapeutics targets patients with cardiovascular, pulmonary, oncology, and organ transplant needs, while advancing a pipeline featuring RemoPro and ralinepag for PAH, Aurora-GT gene therapy for lung vascular rebuilding, nebulized Tyvaso for IPF, and xenotransplantation technologies including UKidney for end-stage renal disease via xenografts, allogenic recellularization, and bioprinting. In recent developments, United Therapeutics announced the first human transplant in its EXPAND clinical trial of UKidney for end-stage renal disease in November 2025, marking a milestone in xenotransplantation; the company reported positive top-line results from the phase 3 TETON-2 pivotal study of nebulized Tyvaso in IPF in September 2025, meeting the primary endpoint and key secondary measures across subgroups; it initiated a $1 billion accelerated share repurchase program in August 2025 with Citibank to return capital to shareholders while supporting growth; and earlier acquired IVEVA and MiroMatrix to bolster organ manufacturing expertise, alongside investments in new manufacturing facilities and designated pathogen-free sites.
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
United Therapeutics Corporation Acquires Thymmune Therapeutics
14 value stocks of companies primed for rapid growth through 2028
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
These 3 Stocks Lowered Their Share Counts Drastically in Q1
Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?
SDZNY or UTHR: Which Is the Better Value Stock Right Now?
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Jim Simons' fund bet early on Micron; Here's the fund's top stocks now
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook